Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

作者
Joyce F. Liu,Stephen A. Cannistra
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:32 (13): 1287-1289 被引量:12
标识
DOI:10.1200/jco.2013.54.7299
摘要

each of these three studies, AURELIA observed a statistically significant benefit in progression-free survival (PFS) with the addition of bevacizumab to chemotherapy, with an absolute 3.3-month improvement in median PFS from 3.4 months in the chemotherapy-alone arm to 6.7 months in the chemotherapy plus bevacizumab arm (hazard ratio, 0.48; 95% CI 0.38 to 0.60; P , .001). This margin of benefit is similar to those reported in the GOG 218, ICON7, and OCEANS studies, which suggests a remarkable consistency in the observed effects of combining bevacizumab with chemotherapy in several different settings in ovarian cancer. However, as with the other randomized phase III studies, no overall survival (OS) benefit was observed in the chemotherapy plus bevacizumab arm in AURELIA. Similar to the OCEANS trial, the combination of bevacizumab and chemotherapy in AURELIA also significantly improved the overall response rate (ORR) from 11.8% to 27.3% ( P 5 .001), as assessed by RECIST criteria. No new safety signals were observed in the chemotherapy plus bevacizumab arm, with the incidence of $ grade 2 hypertension and proteinuria being similar to that of other studies. The incidence of $ grade 2 GI perforation was 2.2% in the chemotherapy plus bevacizumab arm compared with 0% in the chemotherapy-alone arm; again, this is consistent with the findings of other studies. Interestingly, the incidence of hand-foot syndrome and peripheral sensory neuropathy was greater in the chemotherapy plus bevacizumab arm compared with chemotherapy alone, which most likely relates to the longer duration of time that patients received either PLD or paclitaxel in the combination arm (because patients remained on chemotherapy for a longer period of time without disease progression). The incidence of treatment-related death was 2.8% in each arm. Importantly, AURELIA also studied PROs as a separate preplanned end point and found that more patients in the chemotherapy plus bevacizumab arm achieved a $ 15% improvement in abdominal/GI symptom PROs (as assessed by the Quality of Life Questionnaire–OV28 abdominal/GI symptom subscale) at week 8 or 9 (21.9% v 9.3%; P 5 .002). 4 This may represent an underestimate of the PRO improvement with chemotherapy plus bevacizumab, given that only 65% of patients in this trial had sufficient symptoms at baseline for a difference to be detectable. It is noteworthy that AURELIA is the first study incorporating bevacizumab in ovarian cancer to report an improvement in PROs. In the setting of platinum-resistant ovarian cancer, in which therapy is palliative, improvement in PROs is of potential importance even in the absence of an OS benefit. In contrast, in the studies incorporating bevacizumab into first-line and subsequent maintenance treatment, GOG 218 did not demonstrate an improvement in PROs, and ICON7 demonstrated a slight worsening in PROs. 8,9 Perhaps it is not surprising that PROs were not improved and were possibly compromised by introducing bevacizumab into the first-line setting, where most patients experience relatively few disease-related symptoms once chemotherapy begins, and when the magnitude of median PFS prolongation with bevacizumab is modest. In the relapsed setting, OCEANS did not include a PRO end point. 7 Although the results reported in these studies add to our experience with bevacizumab in ovarian cancer, interpreting the data from these reports is not straightforward. AURELIA differs from GOG 218 and OCEANS in that it is an open-label study without a placebo

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
yyyy完成签到,获得积分10
1秒前
天天快乐的应助被幸福的襄采纳,获得10
1秒前
Tuotuo完成签到 ,获得积分10
1秒前
gao完成签到,获得积分10
2秒前
笑笑笑先生完成签到,获得积分10
2秒前
苗条元柏完成签到,获得积分10
2秒前
2秒前
学术新星完成签到,获得积分10
2秒前
2秒前
zhao完成签到,获得积分10
2秒前
应急食品完成签到,获得积分10
3秒前
小小小先生的应助被科研人采纳,获得10
3秒前
Jiannuk完成签到,获得积分10
3秒前
gulu完成签到,获得积分20
3秒前
优雅的怀莲完成签到,获得积分10
3秒前
4秒前
小蘑材完成签到,获得积分10
4秒前
PsyQin完成签到,获得积分10
4秒前
六边形猪宝完成签到 ,获得积分10
4秒前
舒心橘子完成签到,获得积分10
4秒前
赤练仙子发布了新的文献求助10
5秒前
Puddingo完成签到,获得积分10
5秒前
野火哈机密完成签到,获得积分10
5秒前
xiaowan完成签到,获得积分10
5秒前
洛宁发布了新的文献求助10
5秒前
5秒前
柏朴完成签到,获得积分10
5秒前
敏感的花卷完成签到,获得积分10
6秒前
6秒前
牛iu发布了新的文献求助10
6秒前
nanchuangjiao完成签到,获得积分10
6秒前
nikola完成签到,获得积分20
6秒前
李健的应助被寒食采纳,获得10
6秒前
goodman完成签到,获得积分10
6秒前
yy完成签到,获得积分10
7秒前
发呆小天才儿完成签到 ,获得积分10
7秒前
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105